MICAL2 as a key effector of β-catenin signaling driving melanoma progression and therapeutic resistance
Abstract
β-catenin plays a pivotal role in oncogenesis through its involvement in cell-cell adhesion, Wnt signaling, and transcriptional regulation. Dysregulation of β-catenin contributes to tumorigenesis by promoting proliferation, bypassing senescence, and enhancing migration and invasion. In melanoma, however, its role has been controversial, with studies reporting conflicting effects on proliferation, metastasis, and patient survival. Here, we demonstrate that activation of β-catenin is associated with a poor prognosis in melanoma. This conclusion is based on immunohistochemical analysis of a cohort of 157 patients and the identification of a genetic signature for melanoma upon β-catenin activation. This signature includes known targets such as APCDD1 and AXIN2, as well as previously unknown targets like MICAL2 and SLC1A5. Notably, MICAL2 (Molecule Interacting with CasL 2) emerged as a key regulator of the invasive phenotype, with high expression levels correlating with adverse outcomes. Functional studies confirmed that MICAL2 is transcriptionally regulated by β-catenin. Nras and Braf mouse melanoma models further validated the conserved regulation of MICAL2 by β-catenin, linking it to melanoma initiation and metastasis. Moreover, MICAL2 expression is enriched in melanoma cells resistant to BRAF inhibitors, and MICAL2 downregulation restores therapeutic sensitivity. These findings highlight MICAL2 as a central effector of β-catenin signaling and a mediator of melanoma progression and resistance. Given the therapeutic challenges of directly targeting β-catenin, inhibiting the enzymatic activity of MICAL2 offers a promising and innovative strategy to improve outcomes in β-catenin-driven melanoma.
Related
- p38α Signaling Is Associated with Pancreatic Ductal Adenocarcinoma Progression and Represents a Potential Therapeutic Vulnerability
- Translated Circular RNAs in Glioblastoma: Emerging Regulators of Tumor Progression, Molecular Heterogeneity and Therapeutic Resistance
- β-Catenin Signaling in Hepatocellular Carcinoma: Mechanisms of Therapeutic Resistance and Emerging Therapeutic Strategies.
- Oncogenic RAS as an adaptive signaling ecosystem: context-dependent vulnerabilities and resistance-informed therapeutic design
- OTUD4 stabilizes CYLD and counteracts BCL3 K63-linked polyubiquitination to suppress melanoma progression
BibTeX
@article{sohier2026mical2,
title = {{MICAL2 as a key effector of β-catenin signaling driving melanoma progression and therapeutic resistance}},
author = {Pierre Sohier and Jérémy H Raymond and Zackie Aktary and Nour Zidi and Lara Araktingi and Nisamanee Charoenchon and Céline Pisibon and Sylvie Caberia and Eric Pasmant and Nicolas Macagno and Véronique Delmas and Caroline Gaudy-Marqueste and Eirikur Steingrimsson and Robert Ballotti and Valérie Petit and Lionel Larue},
journal = {Cell Death and Differentiation},
year = {2026},
month = aug,
doi = {10.1038/s41418-026-01811-9},
url = {https://hal.science/hal-05848676v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - MICAL2 as a key effector of β-catenin signaling driving melanoma progression and therapeutic resistance
AU - Pierre Sohier
AU - Jérémy H Raymond
AU - Zackie Aktary
AU - Nour Zidi
AU - Lara Araktingi
AU - Nisamanee Charoenchon
AU - Céline Pisibon
AU - Sylvie Caberia
AU - Eric Pasmant
AU - Nicolas Macagno
AU - Véronique Delmas
AU - Caroline Gaudy-Marqueste
AU - Eirikur Steingrimsson
AU - Robert Ballotti
AU - Valérie Petit
AU - Lionel Larue
PY - 2026
DA - 2026/08/14
JO - Cell Death and Differentiation
DO - 10.1038/s41418-026-01811-9
UR - https://hal.science/hal-05848676v1
AB - β-catenin plays a pivotal role in oncogenesis through its involvement in cell-cell adhesion, Wnt signaling, and transcriptional regulation. Dysregulation of β-catenin contributes to tumorigenesis by promoting proliferation, bypassing senescence, and enhancing migration and invasion. In melanoma, however, its role has been controversial, with studies reporting conflicting effects on proliferation, metastasis, and patient survival. Here, we demonstrate that activation of β-catenin is associated with a poor prognosis in melanoma. This conclusion is based on immunohistochemical analysis of a cohort of 157 patients and the identification of a genetic signature for melanoma upon β-catenin activation. This signature includes known targets such as APCDD1 and AXIN2, as well as previously unknown targets like MICAL2 and SLC1A5. Notably, MICAL2 (Molecule Interacting with CasL 2) emerged as a key regulator of the invasive phenotype, with high expression levels correlating with adverse outcomes. Functional studies confirmed that MICAL2 is transcriptionally regulated by β-catenin. Nras and Braf mouse melanoma models further validated the conserved regulation of MICAL2 by β-catenin, linking it to melanoma initiation and metastasis. Moreover, MICAL2 expression is enriched in melanoma cells resistant to BRAF inhibitors, and MICAL2 downregulation restores therapeutic sensitivity. These findings highlight MICAL2 as a central effector of β-catenin signaling and a mediator of melanoma progression and resistance. Given the therapeutic challenges of directly targeting β-catenin, inhibiting the enzymatic activity of MICAL2 offers a promising and innovative strategy to improve outcomes in β-catenin-driven melanoma.
SN - 1350-9047
SN - 1476-5403
ER -